title: Ablation of pituitary pro-opiomelanocortin (POMC) cells produces alterations in hypothalamic POMC mRNA levels and midbrain mu opioid receptor binding in a conditional transgenic mouse model.
abstract: The hypothalamic-pituitary-adrenal (HPA) axis is regulated by stress-related excitatory inputs, and various inhibitory and negative-feedback controls by glucocorticoids and opioids, including pro-opiomelanocortin (POMC)-derived peptides. The role of POMC-derived peptides of pituitary origin in the modulation of brain POMC mRNA expression and opioid receptor binding was investigated using a line of transgenic mice that express a fusion gene composed of the pituitary expression-specific promoter region of the POMC gene driving the herpes simplex viral-1 thymidine kinase (TK). Male adult mice were treated with the antiherpes agent ganciclovir that selectively ablates cells expressing TK. Following treatment, POMC mRNA levels, measured by quantitative solution hybridization/RNase protection assays, were decreased by 48% in the pituitary of the TK+/+ mice, reflecting an expected loss of the pituitary corticotrope POMC cells. This treatment also significantly lowered pituitary beta-endorphin immunoreactivity content and plasma concentrations of corticosterone. In contrast, POMC mRNA levels were increased by 79% in the hypothalamus of the TK+/+ mice with pituitary POMC cell ablation. Binding of [(3)H]DAMGO to mu opioid receptors, as measured by quantitative autoradiography, was significantly reduced in several brain regions including the central grey, median raphe and superficial grey layer of the superior colliculus. These regions are innervated by hypothalamic POMC neurones. No significant differences in binding to either kappa or delta opioid receptors were found in the brain regions studied. These results suggest that POMC-derived peptides of pituitary origin may exert a tonic negative-feedback effect on hypothalamic POMC neurones. In turn, the downregulation of central mu opioid receptors in this model may be mediated through a mechanism related to hypothalamic POMC overexpression.
authors.affiliation: Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY 10021, USA. zhouya@mail.rockefeller.edu
authors.forename: Y
authors.initials: Y
authors.lastname: Zhou
authors.forename: E M
authors.initials: EM
authors.lastname: Unterwald
authors.forename: A
authors.initials: A
authors.lastname: Ho
authors.forename: K S
authors.initials: KS
authors.lastname: LaForge
authors.forename: V P
authors.initials: VP
authors.lastname: Yuferov
authors.forename: J
authors.initials: J
authors.lastname: Kreuter
authors.forename: M J
authors.initials: MJ
authors.lastname: Sirianni
authors.forename: R G
authors.initials: RG
authors.lastname: Allen
authors.forename: M J
authors.initials: MJ
authors.lastname: Kreek
mesh_terms: D000679:Amygdala / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000378:metabolism; D003345:Corticosterone / Q000097:blood; D003346:Corticotropin-Releasing Hormone / Q000235:genetics; D005625:Frontal Lobe / Q000378:metabolism; D007031:Hypothalamus / Q000378:metabolism*; D008297:Male; D008636:Mesencephalon / Q000378:metabolism*; D051379:Mice; D008822:Mice, Transgenic / Q000235:genetics; D010902:Pituitary Gland / Q000166:cytology / Q000378:metabolism*; D011333:Pro-Opiomelanocortin / Q000235:genetics / Q000502:physiology*; D011505:Protein-Tyrosine Kinases / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism*; D018019:Receptors, Corticotropin-Releasing Hormone / Q000235:genetics; D017450:Receptors, Opioid, mu / Q000378:metabolism*; D014018:Tissue Distribution
chemical_list: D012333:RNA, Messenger; D018019:Receptors, Corticotropin-Releasing Hormone; D017450:Receptors, Opioid, mu; D011333:Pro-Opiomelanocortin; D003346:Corticotropin-Releasing Hormone; D011505:Protein-Tyrosine Kinases; D003345:Corticosterone